The HCC patient-journey study: a prospective, adaptive, master protocol, to assess the value of the available sequences of treatment for patients with advanced hepatocellular carcinoma. The Journey of liver cancer patient - J-LI

Status

Not yet recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2026-525898-39-00

Enrollment

1700

Registered

2026-08-14

Start date

Unknown

Completion date

Unknown

Last updated

2026-08-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced hepatocellular carcinoma

Brief summary

OS (Overall Survival)

Detailed description

Progression-free survival (PFS), overall response rate (ORR), quality of life (QoL), and safety/tolerability, financial toxicity, prognostic and predictive value of geriatric assessment parameters in the elderly population assessed through ADL, IADL, and G8 questionnaires, healthcare resource utilization, treatment costs, cost-effectiveness and cost-utility

Interventions

DRUGCABOZANTINIB

DRUGATEZOLIZUMAB

DRUGDURVALUMAB

DRUGBEVACIZUMAB

DRUGREGORAFENIB

DRUGLENVATINIB

DRUGTREMELIMUMAB

DRUGSORAFENIB

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
OS (Overall Survival)	—

Secondary

Measure	Time frame
Progression-free survival (PFS), overall response rate (ORR), quality of life (QoL), and safety/tolerability, financial toxicity, prognostic and predictive value of geriatric assessment parameters in the elderly population assessed through ADL, IADL, and G8 questionnaires, healthcare resource utilization, treatment costs, cost-effectiveness and cost-utility	—

Outcome results

None listed

Source: EU CTIS · Data processed: Aug 15, 2026